Cell and Gene Therapy: Manufacturing Scale-Up and Clinical Progress
Cell and gene therapy approvals reached 18 new medicines in 2024 with manufacturing capacity constraints limiting patient access. CAR-T cell therapy manufacturing capacity reached 280K procedures annually, growing 45% from 2023. Manufacturing costs for individualized cell therapies ranged from $150K-400K per patient, creating economics pressure for cost reduction through process innovation.
Drivers, Challenges & Trends
Key Market Drivers
Market growth expected at strong CAGR through the forecast period, driven by rising demand, technology adoption, and expanding end-user applications globally.
Growth Challenges
Complex regulatory landscapes, high R&D costs, supply chain constraints, and competitive intensity present challenges for market participants.
Emerging Trends
Digital transformation, AI integration, sustainability initiatives, and evolving consumer preferences are reshaping industry dynamics and creating new opportunities.
Strategic Opportunities
Regional expansion, product innovation, strategic partnerships, and technology-enabled solutions offer significant growth potential for forward-looking companies.
What's Inside the Report
- Executive Summary
- Cell/Gene Therapy Landscape
- CAR-T Development
- Gene Editing Approaches
- Manufacturing Challenges
- Cost Economics
- Clinical Efficacy
- Regulatory Pathway
- Appendix
Sample Report Content
Get a glimpse of the comprehensive analysis included in this report.
Market Overview
Cell and gene therapy approvals reached 18 new medicines in 2024 with manufacturing capacity constraints limiting patient access. CAR-T cell therapy manufacturing capacity reached 280K procedures annually, growing 45% from 2023. Manufacturing costs for individualized cell therapies ranged from $150K-400K per patient, creating economics pressure for cost reduction through process innovation.
Market Segmentation Breakdown
By Type
By Application
By Distribution Channel
By Region
Our Research Approach
Cell therapy program tracking, 200 pharma executive interviews, manufacturing capacity assessment, cost analysis
Data Sources
Companies Profiled
Strategic profiles of key players with SWOT analysis, financials, product portfolios, and recent developments included in this report.